Envista(NVST) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q4 2025, Envista reported sales of $751 million, with core sales increasing by 10.8% year-over-year, benefiting from foreign exchange (FX) which added nearly 400 basis points [16][20] - Adjusted EBITDA margin for Q4 was 14.8%, a 90 basis point improvement from the previous year, driven by volume, price, and productivity [17][19] - Adjusted EPS for Q4 was $0.38, up more than 50% from Q4 2024, supported by strong operating profits and share repurchases [13][17] - For the full year 2025, sales reached $2.7 billion, with core sales increasing by 6.5% [19] Business Line Data and Key Metrics Changes - Specialty products and technologies revenue grew nearly 16% year-over-year, with core sales up 10.9% [22] - The orthodontics business, including Spark, saw high single-digit growth, with brackets and wires up double digits year-over-year [22][25] - The implants segment grew mid-single digits globally, with strong performance in digital and regenerative segments [23] Market Data and Key Metrics Changes - The North American diagnostic market returned to growth in the second half of 2025, marking the third consecutive quarter of positive growth across all business lines [32] - The overall global implant market is estimated to be growing mid-single digits, with Envista slightly outperforming this growth [70] Company Strategy and Development Direction - Envista's value creation plan focuses on growth, operations, and people, aiming for 2%-4% core growth, 4%-7% EBITDA growth, and 7%-10% EPS growth [6][31] - The company is committed to continuous improvement and innovation, with significant investments in R&D and new product launches planned for 2026 [8][12] Management's Comments on Operating Environment and Future Outlook - Management noted that the dental market remains slow but stable, with signs of improvement beginning to emerge [32] - The guidance for 2026 includes core revenue growth of 2%-4%, adjusted EBITDA growth of 7%-13%, and adjusted EPS growth of 13%-22% [14][27] Other Important Information - Envista implemented a $250 million share repurchase program in early 2025, returning over $160 million to shareholders throughout the year [9][27] - The company achieved a free cash flow conversion of 114% for 2025, with $231 million in free cash flow generated [26][19] Q&A Session Summary Question: Can you discuss guidance and potential upsides and risks? - Management highlighted that the core guidance for 2026 is 2%-4%, with upsides including market momentum and potential improvements in diagnostics and consumables [37][39] - Risks include macroeconomic volatility and uncertainties in the Chinese market [41][42] Question: What are the assumptions regarding VBP for ortho and implants? - Management expects first-round VBP for ortho and second-round VBP for implants in 2026, but specific timing remains uncertain [54][55] Question: How did Envista achieve higher growth in Q4 compared to previous guidance? - Management attributed the growth to a stronger than expected performance in the China ortho market and improved results in implants [64][66] Question: How does Envista's growth in implants compare to the market? - Envista outgrew the global implant market, which is growing mid-single digits, due to significant investments in the commercial front end and customer training [70]